Drug intelligence / Profile preview

Perineline

Development stage: Preclinical
Lead developer: NeuroSolv Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

Perineline is a two-part, non-surgical therapy developed by NeuroSolv Therapeutics for the treatment of spinal cord injury. The therapy consists of an oral medication combined with neural signaling interventions. Its mechanism of action involves temporarily removing the protective perineuronal nets (PNNs) and signal-blocking glial scars on the surface of spinal cord neurons. By modulating these inhibitory structures, Perineline aims to enable the creation of new synapses and promote neural repair and regeneration in both acute and chronic cases of spinal cord injury. The drug has received Orphan Drug Designation from the European Medicines Agency (EMA) and is being prepared for clinical trials in the United States.

Brand names: Perineline

Targets

CSPG (Chondroitin sulfate proteoglycan)

Beyond the preview

Go deeper on Perineline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Perineline.

Explore the full profile